Instructions for Derinat (sodium deoxyribonucleotide) 5 ampoules
Description sodium deoxyribonucleotide
The solution for I/M introduction is transparent, colorless, without foreign inclusions.
1 ml 1 fl.
sodium deoxyribonucleate 15 mg 75 mg
(from salmon milk)
Auxiliary substances: sodium chloride (0.9 g), water d / and (up to 100 ml).
5 ml - bottles (5) - blisters (1) - cardboard packs.
5 ml - ampoules (5) - contour plastic packages (1) - cardboard packs.
5 ml - ampoules (10) - contour plastic packages (1) - cardboard packs.
ATX codes Derinat
L03A Immunostimulators
Clinical and pharmacological groups / Group affiliation Derinat
Immunomodulator
Active ingredient Derinat
sodium deoxyribonucleate
Pharmacotherapeutic group sodium deoxyribonucleotide
Immunomodulatory agent
Retention conditions sodium deoxyribonucleotide
The drug should be kept out of reach of children, in a dry, light-proof place at a temperature of 4° to 20° C.
Expiration date
The shelf life is 5 years.
pharmachologic effect Derinat
Derynate® is an immunomodulator that affects cellular and humoral immunity. It stimulates the activation of B cells and T helper cells, which enhances the body's immune response to bacterial, viral and fungal antigens. Derinate® also activates nonspecific resistance in the body, optimizing inflammatory responses and stimulating reparative and regenerative processes.
This drug increases the body’s resistance to infection and regulates hematopoiesis by normalizing the number of white blood cells, lymphocytes, granulocytes, phagocytes, and platelets. It also improves lymphatic system function by enhancing drainage and detoxification processes.
Derinate® also has anti-tumor properties, reducing cell sensitivity to the damaging effects of chemotherapy drugs and radiation therapy.
Testimony sodium deoxyribonucleotide
- Oncological diseases: radiation lesions, myelodepression, cytostatic resistance, stomatitis induced by cytostatic therapy.
- Gastrointestinal diseases: gastric and duodenal ulcers, erosive gastroduodenitis, coronary artery disease (CAD).
- Vascular diseases: obliterative diseases of the lower extremities, trophic ulcers.
- Infectious diseases: odontogenic sepsis, purulent septic complications, chlamydia, ureaplasmosis, mycoplasmosis, endometritis, salpingoophoritis, pulmonary tuberculosis,
- inflammatory diseases of the respiratory tract.
- Rheumatic diseases: rheumatoid arthritis.
- Pre- and post-operative: surgical practice.
- Genitourinary system diseases: prostatitis, benign prostatic hyperplasia.
- Respiratory system diseases: chronic obstructive pulmonary diseases.
Method of use, course and dosage Derinat
Derinate® is given by adults intramuscularly (over 1 to 2 minutes) in a mean single dose of 75 mg (5 mL of a 15-mg/mL IM solution) given 24 to 72 hours apart.
- For coronary artery disease, Derinate® is given 5 mL of 15 mg/mL solution IM 48 to 72 hours later and is treated with 10 injections.
For gastric and duodenal ulcers, Derinate® is given 5 mL of 15 mg/mL solution IM at 48 hours, a treatment course of 5 injections.
For cancer, Derinate® is given 5 mL (75 mg/day) IM 24 to 72 hours later with 10 injections.
In gynecology (endometritis, chlamydia, ureaplasmosis, mycoplasmosis, salpingoophoritis, myomas, endometriosis) Derinate® is given 5 ml of solution 15 mg/ml IM in 24-48 hours, the course of treatment is 10 injections.
In andrology (prostatitis, benign prostatic hyperplasia), Derynate® is given IM 5 mL of 15 mg/mL solution in 24 to 48 hours, a treatment course of 10 injections.
For tuberculosis, Derinate® is given 5 mL of 15 mg/mL solution IM in 24 to 48 hours, which is treated with 10 to 15 injections.
For acute inflammatory disease, Derinate® is given 5 mL of 15 mg/mL solution IM 24 to 72 hours later and is treated with 3 to 5 injections.
- For chronic inflammatory disease, Derinate® is given 5 mL of 15 mg/mL solution IM. The first 5 injections are given 24 hours apart, each 72 hours apart, and the overall treatment is 10 injections.
If 15 mg/mL of 2 mL IM solution is used, it is given daily and recalculated until the exchange rate of 375 to 750 mg is reached.
In children, the intramuscular injection rate is the same as in adults. Children up to 2 years of age receive an average single dose of 7.5 mg (0.5 mL of 15 mg/mL IM solution); children 2 to 10 years of age receive a single dose at 0.5 mL per year of life; children over 10 years of age receive a median single dose of 75 mg (5 mL of 15 mg/mL IM solution); and body dose of up to 5 injections.
- Nosology sodium deoxyribonucleotide (ICD codes)
- A15
- Tuberculosis of respiratory organs, confirmed by bacterial and histological culture
- A40
- Streptococcal sepsis
- A41
- Other sepsis
- A56.0
- Lower genitourinary chlamydial infections
- A56.1
- Chlamydial infections of pelvis and other genitourinary organs
- B96.0
- Mycoplasma pneumoniae [M.pneumoniae] as the cause of diseases classified elsewhere
- D25
- Uterine leiomyoma
- D75.8
- Other specified diseases of blood and blood-forming organs
- I20
- Angina [pectoral toad]
- I73.0
- Raynaud's syndrome
- I73.1
- Thromboangiitis obliterans [Berger disease]
- I73.8
- Other specified peripheral vascular diseases
- I73.9
- Peripheral vascular disease, unspecified (including intermittent claudication, arterial spasm)
- I79.2
- Peripheral angiopathy in diseases classified elsewhere (including diabetic angiopathy)
- I83.2
- Varicose veins of lower extremities with ulcer and inflammation
- J04
- Acute laryngitis and tracheitis
- J20
- Acute bronchitis
- J37
- Chronic laryngitis and laryngotracheitis
- J42
- Chronic bronchitis, unspecified
- J44
- Other chronic obstructive pulmonary disease
- K12
- Stomatitis and allied lesions
- K25
- Gastric ulcer
- K26
- Duodenal ulcer
- K29
- Gastritis and duodenitis
- L89
- Decubitus ulcer/pressure area
- L98.4
- Chronic skin ulcer, not elsewhere classified
- M05
- Seropositive rheumatoid arthritis
- N40
- Prostatic hyperplasia
- N41
- Inflammatory diseases of prostate
- N70
- Salpingitis and oophoritis
- N71
- Inflammatory disease of uterus, except cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
- N80
- Endometriosis
- T30
- Thermal and chemical burns of unspecified site
- T66
- Unspecified effects of radiation (radiation sickness)
- Z98.8
- Other specified postsurgical conditions
